Champions Oncology (CSBR) Q4 2026 Earnings Call Summary

1Key Financial Results and Metrics

Fourth Quarter Revenue: $13.8 million, up 12% year-over-year.

Full Year Revenue: Record $59.4 million, driven primarily by a 12% increase in core study services.

Adjusted EBITDA: Fourth quarter adjusted EBITDA of $158,000; full year adjusted EBITDA of $1.6 million, marking positive adjusted EBITDA for each quarter for the first time since fiscal 2022.

Gross Margin: Improved to 51% in Q4 from 41% in the prior year; full year gross margin increased to 48% from 46%.

Cash Position: Ended the year with $4.9 million in cash and no debt.

2Strategic Updates and Business Highlights

Core Services Growth: The translational oncology services business achieved its strongest year, with services revenue reaching $58.7 million.

Data Business: Data license revenue fell to $800,000 from $4.7 million in the prior year due to the absence of a large transaction. However, the customer base expanded significantly, and the pipeline for future opportunities grew.

Corellia Development: The therapeutic subsidiary showed promising data, with ongoing discussions for external funding to support its growth.

3Forward Guidance and Outlook

Fiscal 2027 Focus: The company aims to maintain positive adjusted EBITDA and continue investments in data and Corellia, with expectations for stronger growth and profitability.

Customer Engagement: Continued emphasis on expanding the customer base and pursuing larger strategic licensing opportunities in the data segment.

4Bad News, Challenges, or Points of Concern

Data Revenue Volatility: The significant drop in data license revenue compared to the prior year is concerning, attributed to the absence of a large transaction and potential fluctuations in future quarters.

Operational Challenges: While there was operational leverage in the core services business, the company acknowledged that growth in services revenue may moderate in the near term.

Funding Environment: The current biotech funding environment poses challenges for securing external funding for Corellia, which could impact future investment strategies.

5Notable Q&A Insights

Operational Efficiency: Management highlighted the importance of bringing radiopharmaceutical activities in-house, which is expected to improve margins further.

Market Positioning: There was discussion around the strategic integration of data and services, particularly how predictive modeling capabilities can enhance drug discovery processes.

Investment Strategy: The company remains committed to evaluating investment opportunities that promise long-term returns, maintaining a disciplined approach to spending. Overall, Champions Oncology demonstrated solid financial performance in fiscal 2026, achieving record revenue and positive adjusted EBITDA while navigating challenges in its data business and seeking growth opportunities in Corellia. The outlook for fiscal 2027 emphasizes continued investment and strategic execution.